Susquehanna analyst James Friedman maintains EPAM Sys (NYSE:EPAM) with a Positive and lowers the price target from $496 to $475.
Marathon Digital Says Co Holds ~$142M In Cash Deposits As Signature Bridge
-SEC Filing-SEC Filing
Susquehanna Maintains Positive on EPAM Sys, Lowers Price Target to $475
Susquehanna analyst James Friedman maintains EPAM Sys (NYSE:EPAM) with a Positive and lowers the price target from $496 to $475.
Related Posts
Better Therapeutics Announces Publication Of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective And Less Costly Than Standard Of Care Alone
Over a lifetime horizonAspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower costStudy suggests that using AspyreRx can
‘Pharma Company Behind FDA-Approved CBD Drug Sues A Dozen Competitors Over Alleged Patent Infringement’ – Marijuana Moment
https://www.marijuanamoment.net/pharma-company-behind-fda-approved-cbd-drug-sues-a-dozen-competitors-over-alleged-patent-infringement/
The drug company behind the CBD-based medication Epidiolex has filed a lawsuit
